The predicted indirectly recognizable human leucocyte antigen (HLA) epitopes (PIRCHE) algorithm is a novel in silico algorithm to determine donor-recipient compatibility. The PIRCHE algorithm determines donor-recipient compatibility by counting the number of mismatched HLA-derived epitopes that are involved in indirect T-cell alloimmune responses; these epitopes are designated as PIRCHE. Over the last few years, the PIRCHE algorithm has been investigated in both hematopoietic stem cell transplantation and solid organ transplantation. This review describes the theory of the algorithm, its application in transplantation, and highlights the future perspectives on the clinical application of the PIRCHE algorithm.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/iji.12359 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Assessing the Predictive Power of PIRCHE-II Scores for the Development of Donor-Specific Antibodies After Simultaneous Pancreas-Kidney Transplantation.
Transpl Int
January 2025
Department of Nephrology, University Hospital Zurich, Zurich, Switzerland.
Article Synopsis
- The study investigates the development of donor-specific antibodies (dnDSA) in simultaneous pancreas/kidney transplant recipients (SPKTRs) compared to kidney transplant recipients (KTRs), finding a higher incidence of dnDSA in SPKTRs at one year post-transplant.
- Independent risk factors for dnDSA development identified include preformed DSA and younger donor age, with high PIRCHE-II scores for HLA-DQ correlating significantly with dnDSA.
- However, the research highlights that total PIRCHE-II scores may not reliably predict dnDSA risk, suggesting caution in using this measure for post-transplant assessment.
Molecular matching tools for allocation and immunosuppression optimization. Ready for primetime?
Curr Opin Organ Transplant
February 2025
PIRCHE AG.
Purpose Of Review: Molecular matching continues to be an important topic in organ transplantation. Over the years, several studies - larger and smaller - supported correlations of molecular incompatibility loads and clinical outcomes. However, their practical utility for clinical decision making remains controversial and there is no consensus on the context in which they should be used.
View Article and Find Full Text PDFQuantifying HLA Mismatches at Epitope Level in Haplo-HSCT: Impact in the Outcome in Strategies Using PTCy.
HLA
November 2024
Department of Hematology, University Hospital of Salamanca, Salamanca, Spain.
Haploidentical haematopoietic stem cell transplantation (haplo-HSCT) is one of the most effective therapies for treating malignant haematological disorders. However, HLA disparities are significant barriers to the success of this process since they increase the risk of graft versus host disease (GvHD). HLA disparities quantification could help to anticipate the probability and degree of GvHD, but the best tool for such quantification remains a challenge.
View Article and Find Full Text PDFPaternal HLA-Derived Epitopes and Live Birth in Secondary Recurrent Pregnancy Loss: New Insights From a Clinical Trial.
HLA
October 2024
Center for Translational Immunology, University Medical Centre Utrecht, Utrecht, The Netherlands.
Recurrent pregnancy loss (RPL), defined as two or more pregnancy losses before the 24th week of gestation, affects 1%-3% of women worldwide. Approximately, 40% of RPL cases are secondary RPL (sRPL), where women have given birth before facing pregnancy losses. The underlying causes of RPL remain unclear, but immune-related factors may play a role.
View Article and Find Full Text PDFImproving long-term kidney allograft survival by rethinking HLA compatibility: from molecular matching to non-HLA genes.
Front Genet
October 2024
NYU Langone Transplant Institute, New York University Langone Health, New York, NY, United States.
Article Synopsis
- Optimizing organ transplant success involves more than just matching Human Leukocyte Antigen (HLA) types; it requires a deeper understanding of both classical and non-classical HLA genes to improve long-term graft survival.
- High-resolution HLA genotyping and advanced tools like eplet mismatch calculators and the PIRCHE-II algorithm can provide better predictions of organ rejection compared to traditional methods.
- While full-scale use of molecular matching in deceased donor organ allocation is not yet feasible, its application in living donations and outpatient management shows promise for improving transplant outcomes.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!